Company Information
Company Profile
Cash Flow Statement
Profit & Loss
Financial Position
Financial Ratio
Industry 制造业
Company Introduction 浙江九洲药业股份有限公司（股票简称：九洲药业，股票代码：603456.SH），成立于1998年，总部位于浙江台州，是全球领先的创新药CDMO企业，为全球药企提供创新药临床前CMC，临床Ⅰ、Ⅱ、Ⅲ期，NDA至商业化上市的一站式的药物研发、生产解决方案和专业服务，树立了国内传统仿制原料药企业转型为创新药CDMO企业的成功典范。 作为绿色制药创新技术领导者，九洲药业掌握具有自主知识产权的前沿绿色制药技术，为客户提供行业领先的技术解决方案，提高研发效率和成功率，降低研发成本。 关爱生命，维护健康。九洲药业致力于成为全球药物创新解决方案的卓越生命健康企业，持续赋能合作伙伴加速创新药上市进程，造福全球病患。
Main Business 化学原料药及医药中间体的研发、生产与销售。
Legal Representative 花莉蓉
Top Executives
董事长：花莉蓉
董事：花晓慧,梅义将,林辉潞,许铭,沙裕杰
独立董事：蒋琦,李继承,俞飚
Top 5 Shareholder
Shareholder name Nature Holding Date
浙江中贝九洲集团有限公司流通A股31.52%30/06/2024
台州市歌德实业有限公司流通A股4.51%30/06/2024
花莉蓉流通A股3.55%30/06/2024
中国工商银行股份有限公司－中欧医疗健康混合型证券投资基金流通A股3.02%30/06/2024
林辉潞流通A股1.94%30/06/2024
Company Secretary 林辉潞
Solicitors 浙江天册律师事务所
Auditors 天健会计师事务所（特殊普通合伙）
Tel No 0576-88706789
Fax No 0576-88706788
Website www.jiuzhoupharma.com
Email 603456@jiuzhoupharma.com;beibei.wang@jiuzhoupharma.com；jh.chen@jiuzhoupharma.com
Company Address
Register: 浙江省台州市椒江区外沙路99号
Office: 浙江省台州市椒江区外沙路99号
Listing Date 10/10/2014
Shares Capital
Shares Capital: 899,435,228
Total A Share: 899,435,228
Listed A Share: 898,106,828
Non-tradable A Share: 1,328,400
Other Share: 0
Total B Share: 0
Total H Share: 0
EPS(RMB)* ¥ 1.160
DPS(RMB)* ¥ 0.500
NBV Per Share(RMB)* ¥ 9.407
Market Capitalization(RMB) 11.065B
Smiley face Only Chinese content is avaliable
N
/
N
 : Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SH-HK Ex-Northbound trade (sell only)
N
/
N
 : Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
* Unadjusted Data
Information provided by: etnet
Terms and Conditions
Risk Disclosure:
The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone.
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources, Nanyang Commercial Bank Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.